DIALOG iQ
CHALLENGE THE THINKING
DEFINING NEW STANDARDS
BEGINSWITH CHALLENGING CONVENTIONAL THINKING

Progress for B. Braun means continually challenging and encouraging all employees, customers, physicians, medical professionals and patients to pursue developments which break new ground and move us forward.

B. Braun’s goal with the Dialog iQ was to challenge the thinking of today’s current practices.

Drawing on over fifty years’ experience in dialysis systems technology – and working in constant dialogue with healthcare professionals – B. Braun is in an excellent position to ask the right questions in order to make a real difference in dialysis.

How can hemodynamic stability be ensured in dialysis patients?

What is the right balance between elimination and retention in HDF?

Which treatment situations require careful online monitoring of dialysis dose?

How can safety and usability improve patient satisfaction?
HEMODYNAMIC STABILITY
The Dialog iQ’s system with two biological inputs gives improved information on the patient’s hemodynamic condition.

Scientific knowledge about the elimination of uremic toxins during HDF has been growing over recent years. Maybe it is not only a matter of elimination anymore.

DIALYSIS DOSE
It is important to measure and achieve appropriate dialysis dose for all patients and in all treatment modes (SNCO, HD, HDF).

SAFETY & USABILITY
Ease of use in dialysis equipment means more time to focus on what is most important – the patients.

Experience how the Dialog iQ can define new standards in renal care.
Download the dedicated app and discover the new Dialog iQ from every angle.

DEFINING NEW STANDARDS
BEGINs WITH CHALLENGING CONVENTIONAL THINKING

Progress for B. Braun means continually challenging and encouraging all employees, customers, physicians, medical professionals and patients to pursue developments which break new ground and move us forward.

B. Braun’s goal with the Dialog iQ was to challenge the thinking of today’s current practices.

Drawing on over fifty years’ experience in dialysis systems technology – and working in constant dialogue with healthcare professionals – B. Braun is in an excellent position to ask the right questions in order to make a real difference in dialysis.

HEMODYNAMIC STABILITY
How can hemodynamic stability be ensured in dialysis patients?
What is the right balance between elimination and retention in HDF?
Which treatment situations require careful online monitoring of dialysis dose?
How can safety and usability improve patient satisfaction?

DIALYSIS DOSE
DEFINING NEW STANDARDS BEGINS WITH CHALLENGING CONVENTIONAL THINKING
DEFINING NEW STANDARDS BEGINS WITH CHALLENGING CONVENTIONAL THINKING
DEFINING NEW STANDARDS BEGINS WITH CHALLENGING CONVENTIONAL THINKING
DEFINING NEW STANDARDS BEGINS WITH CHALLENGING CONVENTIONAL THINKING
DEFINING NEW STANDARDS BEGINS WITH CHALLENGING CONVENTIONAL THINKING
HEMODYNAMIC STABILITY

ABPM – Automatic blood pressure measurement
· The most direct insight into a patient’s hemodynamic status
· New system increases patient comfort by reducing the pressures of actual measurement and the time required

BIOLOGIC FUSION is system intelligence
· Two biological input parameters - blood pressure and relative blood volume
· Adaptive system that learns, supporting patient individualization

RELATIVE BLOOD VOLUME is a good addition to blood pressure readings
· Gives insight into vascular refilling
· No additional disposables required

OXYGEN SATURATION gives a new insight into the patient’s condition
· Continuous monitoring of arterial (fistula) or venous (catheter) oxygen saturation during treatment
· Clinical observations suggest that intradialytic hypoxemias are associated with morbid events such as hypotension and cramps1

SIX INDEPENDENT PROFILES are designed for full patient individualization
· The only dialysis system with temperature, dialysate and heparin profiles
· Patient profiles are easily stored with NEXADIA or with patient card

GOOD TO KNOW ...
Blood volume monitoring alone is not sufficient to ensure hemodynamic stability in dialysis patients.2

REFERENCES
INTRODUCTION TO HEMODIALYSIS

The focus to date in convective therapies has been the efficient elimination of uremic toxins. In particular, the subgroup of middle molecules is a point of medical and scientific discussion. However, attention must also be drawn to substances that should be retained, e.g., proteins such as serum albumin.

IMPORTANT OF SERUM ALBUMIN

• Marker for nutritional and inflammatory status of maintenance dialysis patients
• Strong predictor for mortality

xevonta allows an efficient elimination of middle molecules and other uremic toxins, but restricts the loss of serum albumin to 1.1 g ± 0.2 g/session with xevonta with the largest surface area of 2.3 m² when used under post-dilution HDF conditions with high convective volumes.

Other state-of-the-art dialyzers were reported to eliminate 3.01 g ± 2.37 g/session (FMC FX60, 1.4 m²) and 4.25 g ± 3.49 g/session (FMC FX Cordiax 60, 1.4 m²) under post-dilution HDF conditions.

GOOD TO KNOW ...

Increasing the convective volume during HDF is associated with significant protein loss, mainly albumin.

References


ADIMEA – THE REAL INSIGHT INTO TREATMENT QUALITY

• Adimea provides more information than a simple clearance monitoring
• Data shown consists of patient, access and dialyzer information
• Not just Kt/V: eKt/V, spKt/V, URR and UV-absorbance curves are also available, providing doctors and clinical staff with valuable additional insights

NEW SINGLE-NEEDLE SYSTEM

is designed for a full treatment quality with only one pump
• Constant flow through the dialyzer – only one blood pump required
• Reduced extracorporeal blood volume is less stressful for patient’s blood
• Clinical data proves a higher volume of blood is treated with Dialog iQ compared to a system using alternately operating pumps
• The mean number of access problems in the first three months after shunt surgery is reduced by half when only Single Needle Treatments are performed in this period.

References

SAFETY & USABILITY

GOOD TO KNOW …
Less blood-air contact reduces the risk of clotting during therapy.2

MORE TIME FOR PATIENT CARE
WHEN SAFETY MEETS USABILITY

RISK PREVENTION
- Risk of blood contamination in the machine is reduced with PODs (Pressure Oscillating Diaphragms)
- Automated loading of DiaStream iQ reduces risk of repetitive strain injuries

ENHANCED SAFETY
- PODs reduce blood-air contact, reducing clotting
- Reduced extracorporeal blood volume, in particular in single-needle therapies
- NEXADIA: Fully bidirectional machine connectivity reduces probability of errors

SIMPLIFIED PREPARATION
- One-touch priming
- DiaStream iQ Multiconnector saves time with automated loading and ejection of bloodline
- Reduced workload in setting up all therapies, especially single-needle

OPTIMIZED WORKFLOW
- Very fast preparation for HD and HDF
- Priming during disinfection
- Presetting of dialysis machine, bedside documentation and automatic saving of therapy parameters with NEXADIA save up to 21 minutes for the nurse per session1

REFERENCES
Learn more about the benefits of the new Dialog iQ and our other innovative products.

For further information, download the dedicated app by scanning the QR code alongside.
Learn more about the benefits of the new Dialog iQ
and our other innovative products.

For further information, download the dedicated app by
scanning the QR code alongside.